Nearly 25 percent of all teens reported being involved in a physical fight in the past year, with higher rates of violent altercations among African-American and Latin-American adolescents than European-American ones.

To find out why, scholars writing in the Journal of Child and Family Studies conducted focus groups with African American and Latino parents regarding teen violence. Result: addressing the parents' attitudes about fighting, involving them in violence prevention programs and tailoring programs to different racial/ethnic groups may improve the effectiveness of prevention programs.

A majority of Americans, 54 percent, say it can be necessary for the government to sacrifice freedoms to fight terrorism.

About 50 percent of Americans think it is acceptable to allow warrantless government analysis of Internet activities and communications--even of American citizens--in order to keep an eye out for suspicious activity, only about 30 percent are against this type of government investigation.

About 18,000 people are severely injured every year in Germany, as determined by Florian Debus and coauthors in a new study published in Deutsches Ärzteblatt International (Dtsch Arztebl Int 2015; 112: 823-9). Earlier investigations, in 2000 and 2006, estimated that more than 32,000 people sustain multiple trauma each year. The newly calculated lower number likely reflects a reduction of severe injuries caused by road traffic and occupational accidents.

Recreational marijuana use is now legal in four states and "medical" marijuana in 23 states. Research on legalization policies has focused largely on direct impact - how they impact marijuana access and use. What is little discussed is that marijuana increases alcohol use.

Alcohol is the world's  most popular drug, the majority of adults in the U.S. imbibe to varying degrees and drinking accounts for almost one-third of driving fatalities annually. If you like pretend money estimates, it is claimed that alcohol use cost $223.5 billion in 2006 alone.

Palbociclib, a new oral drug with efficacy in combating breast cancer both alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional research in JAMA Oncology.

Palbociclib targets the rapid division of tumor cells by inhibiting the activity of the enzymes CDK4 and CDK6, which propel cell division and increase in number in most cancers. It is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.

Nearly one in four publicly sponsored cancer clinical trials fail to enroll enough participants, which means progress is impeded and a lot of time and money has been wasted.

What accounts for that? Patients grumble about cost - if you go to Stanford Medical for a consultation about a trial they are doing, you are likely to get a large bill just for the visit - and then there is the risk of side effects that get so much media attention. If real medicines that survived 12 years and $2 billion end up with lawsuits for harm, untested treatments or techniques are likely to be worse. And Big Pharma is evil, activists and the federal government routinely tell us.